ASCVD Risk Reduction in Persons with Hypertriglyceridemia: Role of Icosapent Ethyl

• Substantial ASCVD risk persists despite low levels of LDL-C and elevated TGs, and their remnants account for a portion of this residual risk.

• Combination therapy of statins with fibrates or niacin has not shown effectiveness and is generally not recommended to reduce ASCVD event risk.

• REDUCE-IT was a landmark trial showing that icosapent ethyl 4 g/day in addition to maximally tolerated statin therapy could reduce ASCVD events significantly. However, its impact on TGs appears not to account for all of the substantial benefits of this therapy.